After a trial shows early intervention prevents hospitalization, the US Food and Drug Administration approves transcatheter ...

Aortic stenosis is a narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body.

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration ...

New findings from real-world experience support the shift in practice to single antiplatelet therapy after transcatheter ...

The Food and Drug Administration has approved an expanded indication for Edwards Lifesciences’ Sapien 3 transcatheter aortic valve replacement platform to include people who have severe aortic ...

Please provide your email address to receive an email when new articles are posted on . A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis.

Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient ...

“There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend ‘watchful waiting’ until symptoms develop,” Dr. Philippe ...

The US Food and Drugs Administration ( FDA) has approved the Sapien 3 transcatheter aortic valve replacement (TAVR) system for use in patients with severe aortic stenosis who are asymptomatic.

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

"There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend 'watchful waiting' until symptoms develop," according to a ...